BridgeBio Pharma
BBIO
BBIO
456 hedge funds and large institutions have $14.9B invested in BridgeBio Pharma in 2026 Q1 according to their latest regulatory filings, with 90 funds opening new positions, 181 increasing their positions, 132 reducing their positions, and 55 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
1.25% more ownership
Funds ownership: 99.16% → 100.4% (+1.2%)
4% more capital invested
Capital invested by funds: $14.4B → $14.9B (+$533M)
27% less funds holding in top 10
Funds holding in top 10: 22 → 16 (-6)
Holders
456
Holding in Top 10
16
Calls
$780M
Puts
$131M
Top Buyers
| 1 | +$179M | |
| 2 | +$158M | |
| 3 | +$103M | |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$88.4M |
| 5 |
Two Sigma Investments
New York
|
+$85.1M |
Top Sellers
| 1 | -$185M | |
| 2 | -$84.9M | |
| 3 | -$52.3M | |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$38.7M |
| 5 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$33.4M |
